Summary
Sun Pharma has joined eight other drugmakers in a White House deal to lower medicine prices for US Medicaid and future innovative medicine launches. This agreement also grants Sun Pharma a two-year delay on Section 232 tariffs, potentially strengthening its position in the crucial US market.